Please assess the completion status of the following clinical trial:

Trial Title: Alrex® Versus Patanol in the Treatment of Seasonal Allergic Conjunctivitis(SAC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who are diagnosed with acute SAC and experience at least grade 4 ocular itching and at least grade 2 bulbar conjunctival injection (redness) in each eye due to seasonal allergy at Visit 1.~Exclusion Criteria:~* Subjects who have a known hypersensitivity to the study medications or their components or contraindications to ocular corticosteroids.~* Subjects who use any of the disallowed medications throughout the duration of the study and during the period indicated prior to Visit 1.~* Subjects who have intraocular pressure (IOP) greater than 21 mm Hg in either eye or any type of glaucoma.~* Subjects who have a history of any severe/serious ocular pathology or medical condition that could result in the subject's inability to complete the study or affect the subject's safety or trial parameters.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Alrex (Type: EXPERIMENTAL): Ophthalmic formulation containing the active ingredient loteprednol etabonate, 0.2%
- Patanol (Type: ACTIVE_COMPARATOR): Ophthalmic solution containing olopatadine, 0.1%

Based on this trial design, predict the completion outcome and termination type (if applicable).